Skip Navigation

Click on any project title for a more detailed description of the project. For more information about any of these awards (e.g., PI contact information or associated publications), please use the corresponding project number to search for information at the NIH Reporter website. Consistent with NIH policy, abstracts are not available for projects receiving their first award within the past year, so descriptions provided below are from the NCI program director.

Current Year | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999

Show/Hide All

Project # Year
of Award
PI Name(s)
Institution Title
Abstract Text (Official)
R21 CA174541-01 2013 BAI, MINGFENG UNIVERSITY OF PITTSBURGH AT PITTSBURGH A Novel Theranostic Platform for Targeted Cancer Therapy and Treatment Monitoring
To develop a new class of near-IR imaging probes via a dendrimer-based approach that allows conjugation with a broad variety of molecules; including targeting agents, other imaging contrast agents (for multimodal imaging) and cytotoxic agents.
R21 CA174583-01 2013 CASTRO, CARLOS E. OHIO STATE UNIVERSITY Nanoscale tools for functional studies of cancer-relevant chromatin modifications
Development of a novel nanoscale caliper tool made using DNA origami to probe chromatin assemblies. Focus is on ability to interrogate nucleosome elements between 10-100 nm intracellularly.
R21 CA174594-01A1 2013 CELEDON, ALFREDO ANDRES TWISTNOSTICS, LLC Single molecule microarrays for the detection of mutant DNA in body fluids
Development of a novel biosensor for mutated DNA based on the tortional topology of DNA molecules twisted by a tethered magnetic bead. Binding of a target sequence that differs by a single mutation is sufficient to induce supercoiling which can be picked up at extremely low limits of detection.
R21 CA182608-01 2013 CHENG, JI-XIN PURDUE UNIVERSITY WEST LAFAYETTE Quantitative Spectroscopic Imaging of Cancer Metabolites in Live Cells and Intact
A new imaging system for label-free imaging of metabolites in individual cells with the ability to resolve dispersion of metabolites across the cells and track them in real-time. Approach involves developing a new rapid multiplexed stimulated Raman scattering tool that leverages a recently developed amplification and optical tuning array, scanning technique and multivariate analysis.
R21 CA177393-01 2013 DOYLE, PATRICK S; FAN, RONG(contact) YALE UNIVERSITY High-throughput, Multiplexed Detection of miRNA Biomarkers in Single Cancer Cells
To develop a single microfluidic chip integrated with a high-density DNA barcode array to enable high-throughput (1000 cells at a time), multiplexed (12 markers) detection of microRNAs from single cells.
R21 CA177519-01 2013 HARISMENDY, OLIVIER(contact); HOWELL, STEPHEN B UNIVERSITY OF CALIFORNIA SAN DIEGO In vivo detection and genome-wide location analysis of DNA-adducts
To develop terminal deoxynucleotidyl transferase-sequencing (TdT-seq) technology which can provide a single nucleotide resolution map of DNA-adducts. Information on the precise location of adducts in normal and tumor DNA will aid in developing strategies and therapeutics which can favorably increase DNA damage in tumor cells and/or prevent damage in normal cells.
R21 CA177447-01 2013 JEFFREY, STEFANIE S STANFORD UNIVERSITY A Droplet-Based System for Capture, Manipulation, and Biochemical Profiling of Ra
To apply the electrowetting-based liquid handling capabilities of the Advanced Liquid Logic platform to isolate single cells from blood in such a way that it yields suspended individual cells available for a variety of molecular analyses as well as culturing. The real advantage to this approach is the potential speed for processing samples, targeting 5 mL of blood in less than an hour is the goal of the R21 phase, but greater degrees of parallelization could reduce this significantly further.
R21 CA174581-01 2013 LAI, JAMES UNIVERSITY OF WASHINGTON Biospecimen preparation technologies to enable high throughput and highly sensitive targeted proteomics
To develop a novel class of affinity reagents for efficient extraction of proteins from urine using novel magnetic nanoparticle beads with polymer-Ab conjugates that aggregate in response to temperature and pH changes.
R21 CA182330-01 2013 LEVY, MATTHEW ALBERT EINSTEIN COLLEGE OF MEDICINE Lectimers: Glycan-anchored scaffold libraries for targeting carbohydrate-binding
To develop a new aptamer-selection like process for generating new carbohydrate-binding agents, called lectimers. Approach is specifically meant to drastically reduce the number of selection cycles required to find a high-affinity binding agent down to a single cycle.
R21 CA177535-01 2013 LIOTTA, LANCE ALLEN GEORGE MASON UNIVERSITY Protein Painting reveals hidden protein-protein interaction domains
To develop a new class of reagents, called ?protein painting?, that will allow the rapid screening of protein-protein interaction domains in solution. The new chemical method comprises of novel synthetic organic small molecules that bind to proteins with high affinity and mask protease cleavage sites, but don?t have access to internal protein-protein contact domains. ?Painted? complexes can then be determined directly by mass spectrometry.
R21 CA174577-01 2013 LU, CHANG VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY Sensitive and integrated microfluidic ChIP assays for studying transcriptional regulation
To develop a microfluidic platform to fully automate chromatin immunoprecipitation assays, with improved speed, sensitivity and reproducibility over current techniques. Platform will be piloted to study intra-tumor heterogeneity and also time-course study of NF kappa-B transcription dynamics in a xenograft model.
R21 CA182333-01 2013 LUKER, GARY D; TAVANA, HOSSEIN(contact) UNIVERSITY OF AKRON A Novel High Throughput Tumor Spheroid Microtechnology
To develop an automated, robotically-controlled platform for uniform growth of tumor spheroids in 384-well plates for drug screening. Platform will be capable of creating spheroids of mixed tumor and stromal cells to screen compounds that target tumor-stroma interactions
R21 CA177402-01 2013 MALY, DUSTIN J; ONG, SHAO-EN(contact) UNIVERSITY OF WASHINGTON Kinase Profiling with Quantititative Chemoproteomics
To develop bivalent affinity reagents for downstream mass spectrometric analysis that can be used to target and enrich for protein complexes interrogating both the post-translational modification state (PTMs) and the enzymatic activity of the complex.
R21 CA182335-01 2013 OZERS, MARY SZATKOWSKI; WARREN, CHRISTOPHER L (contact) ILLUMAVISTA BIOSCIENCES, LLC High Density Peptide Arrays for Cancer-Related Post-Translational Modifications
To develop a high-throughput peptide array, which ultimately allows for representation of the known human proteome in 17-AA strands on a single standard microscope slide platform, with redundancy. Array will then be exposed to purified enzymes to study post-translational modifications.
R21 CA173243-01A1 2013 PAN, TINGRUI UNIVERSITY OF CALIFORNIA DAVIS Digital one-disc-one-compound array for high-throughput discovery of cancer-targe
Develop digital One-Disc-One-Compound (ODOC), an enabling technology that integrates novel combinatorial chemical methods, encoding, and matrix methods on a microfluidics platform for the discovery of cancer-targeting molecules. The proposed device also allows for high-throughput characterization of binding affinities.
R21 CA177526-01 2013 QUINN, THOMAS P (contact); ROBILLARD, MARC UNIVERSITY OF MISSOURI-COLUMBIA In vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy
To optimize pre-targeted radioimmunotherapy (RIT) using novel in vivo cyclooctene and tetrazine cyclo-addition chemistry. Approach aims to overcome non-specific irradiation of normal tissue due to slow clearance of radiolabeled monoclonal antibodies (mAbs) from circulation.
R21 CA173279-01A1 2013 SOPER, STEVEN ALLAN UNIVERSITY OF NORTH CAROLINA CHAPEL HILL Acute Myeloid Leukemia: MRD Analysis Using Modular uFluidics and uFlow Cytometry
To improve outcomes for treatment of acute myeloid leukemia (AML) by developing an inexpensive and fully-automated microfluidic, multi-parameter flow cytometry (MFC) platform to detect the onset of minimum residual disease (MRD) AML from peripheral blood with high sensitivity. Platform could provide a robust, inexpensive method to allow frequent testing with high sensitivity and specificity for relapse for AML.
R21 CA174611-01A1 2013 VAN DAM, ROBERT MICHAEL UNIVERSITY OF CALIFORNIA LOS ANGELES Compact microfluidic PET probe concentrator for preclinical and in vitro imaging
To broaden the availability of various PET probes for research by miniaturization of PET probe purification to overcome issues with traditional processes. Platform is meant to replace rotary evaporator or HPLC driven purification and complement parallel efforts to create benchtop probe synthesizers.
R21 CA182322-01 2013 WANG, ANDREW ZHUANG UNIVERSITY OF NORTH CAROLINA CHAPEL HILL Development of 3D organ-specific models of colorectal cancer metastasis
A develop a novel 3D culture chamber that more appropriately recapitulates the tumor microenvironment. The design is based on recent tissue engineering advances using decellularized ECM scaffolds, which preserve important growth factors and cytokines, then seed and grow various cell populations.
R21 CA181859-01 2013 WANG, ZHENGHE CASE WESTERN RESERVE UNIVERSITY Next-generation mouse gene-targeting technology to model tumorigenesis
To develop a fast, cost-effective method for creating genetically engineered mice by applying a new homologous recombination method using recombinant virus. The primary advantage over a new CRISPR-based technique is genome-wide targeting capacity and easier implementation.
R21 CA174608-01 2013 WILLIAMS, JOHN CHARLES CITY OF HOPE/BECKMAN RESEARCH INSTITUTE Optimization of multivalent ligands by super-resolution microscopy to treat cancer
Application of a newly developed class of engineered multi-valent peptides (meditopes) for enhanced diagnostic imaging and possibly enhance immune-based therapies. Proposal involves application of PC-PALM super-resolution imaging to drive design of meditopes for tracking cell surface receptor clustering.
R21 CA182341-01 2013 WILSON, JAMES NORBERT UNIVERSITY OF MIAMI CORAL GABLES Kinase Binding Fluorescent Probes for Assaying Cellular Receptor Populations
Combining small molecule inhibitors and molecular dyes through a rotatable linker to yield kinase-specific fluorescent probes that turn on upon binding their target, thereby enabling real-time analysis of critical cancer-relevant signaling pathways.
R33 CA177462-01 2013 BAILEY, RYAN C (contact); JOHNSON, MARK D UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN Meso-plex miRNA and protein profiling for cancer diagnostics using chip-integrate
To develop and validate a highly-scalable, low-cost, multiplex biosensor array based on a photonic resonator silicon micro-rings platform. The target platform will exhibit high sensitivity (<1fM) and specificity for up to 30 unique miRNA and 18 unique proteins, simultaneously and with redundancy, in the same sample on a single array.
R33 CA182377-01 2013 BROWN, BRIAN DAVID (contact); SACHIDANANDAM, RAVI MOUNT SINAI SCHOOL OF MEDICINE Sensor-seq: A genome-wide biological measure of microRNA activity.
To develop the Sensor-Seq platform, which consists of a lentiviral vector library with tethered fluorescing groups that will emit on binding to their target miRNA to quantitate the activity of each miRNA in a cell. They propose to expand their library of some 282 binding vectors to target all known human and murine miRNAs (>3000) and to generate better tools for handling the vectors and interpreting the readout. The platform will be demonstrated with human cancer cells and exosomes.
R33 CA177446-01 2013 CUNNINGHAM, BRIAN T. (contact); ZANGAR, RICHARD C UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN Photonic Crystal Enhanced Fluorescence: Development of Sensors Structures and Det
To develop and validate a highly sensitive, multiplexed, rapid, and automated point-of-care assay platform, based on photonic crystal enhanced fluorescence, to yield a novel microarray ELISA that can perform biomarker analysis on a droplet (3-5?L) of plasma. A panel of breast cancer biomarkers will be evaluated in the proposed project.
R33 CA177456-01 2013 DI CARLO, DINO UNIVERSITY OF CALIFORNIA LOS ANGELES Isolating circulating tumor cells using a centrifuge on a chip
The optimization and validation of a novel size-based separation technology (the Centrifuge Chip) that employs inertial lift force for enrichment of viable circulating tumor cells (CTCs) from whole blood. Purified CTCs isolated by this device are readily available for analysis by traditional cytology or molecular analysis techniques.
R33 CA174616-01A1 2013 FRANCIS, MATTHEW B; HSIAO, SHIH-CHIA(contact) ADHEREN, INC. The development of a microscopy-based cell-array toxicity assay for quantifying C
To develop a platform that immobilizes whole cells on a prepared surface by DNA linkers in a grid formation, based on a new DNA-based adhesion technology called programmable cell adhesion. This platform allows for real-time optical tracking of individual cellular antibody-dependent and complement-dependent cytotoxicity.
R33 CA177461-01 2013 FURDUI, CRISTINA(contact); POOLE, LESLIE B WAKE FOREST UNIVERSITY HEALTH SCIENCES New Reagents for Tracking Protein Oxidation in Cells by MS and Imaging Methods
To increase the functionality of emerging chemical reagents for the detection of proteins containing sulfenic acid modifications by adding imaging and modification site identification capabilities. The intent is to provide reagents needed for the analysis of redox regulation and protein oxidation in the development and progression of cancer.
R33 CA174575-01 2013 JI, HANLEE STANFORD UNIVERSITY Oligonucleotide-Selective Sequencing for integrated and rapid cancer genome analysis
To optimize and miniaturize the Oligonucleotide-Selective Sequencing (OS-Seq) technique on a microfluidic platform.
R33 CA174550-01 2013 KAMM, ROGER D. MASSACHUSETTS INSTITUTE OF TECHNOLOGY Microfluidic 3D Assays for Metastatic Cancer
To further develop and validate a 3D metastasis assay that offers exquisite control of microenvironment components.
R33 CA173373-01A1 2013 KUHN, PETER SCRIPPS RESEARCH INSTITUTE Clinical validation of the HD-CTC fluid biopsy in early detection of lung cancer.
To validate and accurately establish the performance characteristics of the HD-CTC Fluid Biopsy platform in a group of patients undergoing evaluation for lung cancer.ÿThe major clinical dilemma resides in the diagnosis of small, image-detected lung nodules. The HD-CTC fluid biopsy may add important clinical information for early diagnosis and staging of small lesions as an adjunct to imaging. The major advance over the current platform is to establish the ability to perform immunocytochemistry (ICC) and fluorescent in situ hybridization (FISH).
R33 CA174554-01A1 2013 LIU, YU-TSUENG ; SIMBERG, DIMITRI(contact) UNIVERSITY OF CALIFORNIA High quality CTC isolation using microbubbles for downstream molecular analysis
To further develop and optimize a micro-bubble based platform for isolating and potentially characterizing circulating tumor cells. The platform exhibits a number of features that may allow it to rise as a superior platform for this application, including short processing time to limit RNA and protein degradation, easy scalability to accommodate a range of sample volumes easily, and greater flexibility in how one might either engage molecular analyses on captured cells or culture them.
R33 CA173300-01A1 2013 PAULOVICH, AMANDA G FRED HUTCHINSON CANCER RESEARCH CENTER Advanced development of immuno-MRM technology to analyze archived cancer tissues
To further develop a novel platform that couples peptide immuno-affinity enrichment to multiple-reaction monitoring (MRM), resulting in highly sensitive immuno-MRM assays (ó100fmol/mg) with small sample requirements for biomarker validation studies. The goal is to validate a newly developed platform that couples peptide immuno-1 affinity enrichment to MRM using cells derived from FFPE samples.
R33 CA177466-01 2013 SCHLEGEL, RICHARD(contact); WELLSTEIN, ANTON GEORGETOWN UNIVERSITY Conditionally reprogrammed cells as a novel tool for biobanking
To further develop a novel conditional cell reprogramming technology that can overcome the limitations associated with traditional cell culture (e.g., insufficient sample available and genotype changes upon culturing). Conditional Reprogrammed Cells (CRCs) can be obtained from cryopreserved tissue augmenting the value of the biospecimens. The goal for this proposal is to optimize and standardize CRCs to produce unlimited amount of tumor and normal cells that reflect the genotype and the spectrum of mutations originally found in the primary tumor and make CRCs widely applicable for biobanking.
R33 CA173264-01A1 2013 TACKETT, ALAN JACKSON UNIVERSITY OF ARKANSAS FOR MED SCIS Development of MassSQUIRM to Quantitatively Measure Lysine Methylation
To advance an emerging technology that combines isotopic labeling with reductive methylation and mass spectrometry (MassSQUIRM) that allows comprehensive and unambiguous quantification of lysine methylation status in histones. The approach is specifically designed to overcome known limitations associated with antibody-based, radiolabeling and direct mass spectrometric approaches.
R33 CA174562-01 2013 TSENG, HSIAN-RONG UNIVERSITY OF CALIFORNIA LOS ANGELES Molecular and Functional Analysis of Single Circulating Melanoma Cells
To combine NanoVelcro CTC capture with laser-capture microdissection.
R33 CA174560-01A1 2013 WEISSLEDER, RALPH ; XIE, XIAOLIANG SUNNEY(contact) HARVARD UNIVERSITY Whole Genome Amplification and Sequencing of Single Cancer Cells
Advanced development of a platform for sorting single cells and subsequent linear genome amplification and sequencing. The platform is specifically being validated as a tool for capturing heterogeneity across captured cells, starting with captured CTCs.